Sino Biopharmaceutical Limited (1177.HK)

HKSE · Healthcare · Biotechnology
5.11 HKD-4.85%As of 2026-11-22 · HKD
Last session low 5.08 HKDLast session high 5.30 HKD
52-week low 4.19 HKD52-week high 7.30 HKD
Market cap (USD)
$11.58B
Sector
Healthcare
P/E (TTM)
34.0x
Dividend yield
2.74%

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in HKD.

IndicatorValueReading
RSI (14)41.3In the neutral range (30 to 70)
MACD (12, 26, 9)0.03Level with its signal line (0.03)
Bollinger %B (20, 2)39%Inside the bands (4.61 to 5.88)
SMA 205.24Price is 2.6% below
SMA 505.38Price is 5.1% below
SMA 2005.42Price is 5.8% below
ATR (20)4.51% of priceAverage true range per day
52-week position29%In the lower part of the 4.19 to 7.30 range

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.

Latest fiscal yearEnded 2025-12-31: revenue of 31.83B CNY and an operating margin of 21.7%.

More in Biotechnology